Schmidt, Boris 1962-
Boris Schmidt researcher (ORCID 0000-0003-1662-2392)
VIAF ID: 4711159613658041030004 (Personal)
Permalink: http://viaf.org/viaf/4711159613658041030004
Preferred Forms
4xx's: Alternate Name Forms (2)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Auf dem Weg zum Aflatoxin M1 und verwandten Strukturen durch homogene Katalyse | |
Biomimetika - ihre Synthese durch Übergangsmetall-katalysierte Schlüsselreaktionen und ihre Anwendung | |
Cell‐Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit | |
Design, synthesis and biological evaluation of novel FKBP51 ligands | |
Design, Synthesis and Evaluation of Reversible and Covalent Binding Serine-Targeted LRRK2 Inhibitors | |
Design und Synthese makrozyklischer FKBP51-Liganden | |
Design und Synthese selektiver Nek1 Inhibitoren | |
Fc Antigen-bindende Fragment-Wirkstoff Konjugate als neues Antikörper-basiertes Format für den zielgerichteten Wirkstofftransport | |
Fc Antigen-Binding Fragment Drug Conjugates as Novel Antibody-Based Format for Targeted Drug Delivery | |
In silico design, synthesis and evaluation of kinase and proteasome inhibitors as well as fluorescent probes. | |
Naturstoffe als Kinase-Inhibitoren: Totalsynthese, In-vitro-Kinase-Aktivität, In-vivo-Toxikologie in Zebrafisch-Embryonen und In-silico-Docking | |
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells | |
Strukturbasiertes Design, Synthese und pharmakologische Evaluation von Proteasom- und FLT3-Inhibitoren in Leukämiemodellen | |
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations |